ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

Kemas kini terakhir: semalam, 9:21AM

227.56

3.19 (1.42%)

  • 1H 1.42%
  • 5H -1.83%
  • 1B 5.40%
  • 6B 21.47%
  • Tahun Ke Tarikh 26.81%
  • 1T 28.96%
  • 5T 112.11%
Penutupan Terdahulu 224.37
Buka 224.84
Jumlah Dagangan 543,605
Purata Dagangan (3B) 5,950,985
Modal Pasaran 402,177,196,032
Harga / Pendapatan (P/E TTM) 172.39
Harga / Pendapatan (P/E Ke hadapan) 16.21
Harga / Jualan (P/S) 6.77
Harga / Buku (P/B) 50.46
Julat 52 Minggu
164.39 (-27%) — 244.81 (7%)
Hasil Dividen (DY TTM) 1.44%
Margin Keuntungan 7.31%
Margin Operasi (TTM) 30.43%
EPS Cair (TTM) 2.35
Pertumbuhan Hasil Suku Tahunan (YOY) 8.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -6.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 4,789.60%
Nisbah Semasa (MRQ) 0.760
Aliran Tunai Operasi (OCF TTM) 16.40 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 16.94 B
Pulangan Atas Aset (ROA TTM) 8.34%
Pulangan Atas Ekuiti (ROE TTM) 88.40%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok AbbVie Inc. Menaik Menaik

AISkor Stockmoo

0.1
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata 0.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ABBV 402 B 1.44% 172.39 50.46
JNJ 488 B 0.61% 19.56 6.24
MRK 252 B 1.60% 13.36 4.55
PFE 146 B 1.67% 14.94 1.55
BMY 106 B 1.19% 17.49 5.40
GSK 97 B 0.81% 13.71 4.52

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.10%
% Dimiliki oleh Institusi 74.87%
Julat 52 Minggu
164.39 (-27%) — 244.81 (7%)
Julat Harga Sasaran
220.00 (-3%) — 289.00 (27%)
Tinggi 289.00 (Piper Sandler, 27.00%) Beli
Median 247.50 (8.77%)
Rendah 220.00 (UBS, -3.32%) Pegang
Purata 248.67 (9.28%)
Jumlah 9 Beli, 3 Pegang
Harga Purata @ Panggilan 221.09
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
UBS 07 Nov 2025 220.00 (-3.32%) Pegang 219.16
Piper Sandler 05 Nov 2025 289.00 (27.00%) Beli 216.77
10 Oct 2025 284.00 (24.80%) Beli 230.50
Citigroup 03 Nov 2025 235.00 (3.27%) Pegang 211.96
JP Morgan 03 Nov 2025 260.00 (14.26%) Beli 211.96
16 Sep 2025 235.00 (3.27%) Beli 216.26
Guggenheim 20 Oct 2025 242.00 (6.35%) Beli 232.06
Raymond James 17 Oct 2025 250.00 (9.86%) Beli 229.57
B of A Securities 03 Oct 2025 251.00 (10.30%) Pegang 233.91
Evercore ISI Group 22 Sep 2025 222.00 (-2.44%) Beli 222.59
Berenberg 17 Sep 2025 270.00 (18.65%) Beli 220.81
Cantor Fitzgerald 15 Sep 2025 245.00 (7.67%) Beli 217.61
BMO Capital 12 Sep 2025 240.00 (5.47%) Beli 218.34
Wells Fargo 12 Sep 2025 260.00 (14.26%) Beli 218.34
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
02 Dec 2025 Pengumuman AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
28 Nov 2025 Pengumuman SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
25 Nov 2025 Pengumuman AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
24 Nov 2025 Pengumuman AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
18 Nov 2025 Pengumuman AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
14 Nov 2025 Pengumuman AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
13 Nov 2025 Pengumuman AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
12 Nov 2025 Pengumuman Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
06 Nov 2025 CNBC Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
31 Oct 2025 Pengumuman AbbVie Reports Third-Quarter 2025 Financial Results
29 Oct 2025 Pengumuman The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
29 Oct 2025 Pengumuman AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
28 Oct 2025 Pengumuman Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM
21 Oct 2025 Pengumuman The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients
20 Oct 2025 Pengumuman RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
17 Oct 2025 Pengumuman AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
13 Oct 2025 Pengumuman U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease
13 Oct 2025 Pengumuman AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
09 Oct 2025 Pengumuman SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer
06 Oct 2025 Pengumuman AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor
02 Oct 2025 Pengumuman AbbVie to Host Third-Quarter 2025 Earnings Conference Call
01 Oct 2025 Pengumuman Natrelle® Awarded Supplier Agreement from Vizient
30 Sep 2025 Pengumuman AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options
30 Sep 2025 Pengumuman AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
29 Sep 2025 Pengumuman AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
29 Sep 2025 Pengumuman AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
26 Sep 2025 Pengumuman AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
25 Sep 2025 Pengumuman Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
23 Sep 2025 Pengumuman Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
09 Sep 2025 Pengumuman BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
05 Sep 2025 Pengumuman AbbVie Declares Quarterly Dividend
Papar semua
Hasil Dividen (DY TTM) 1.44%
Purata Hasil Dividen 5T 3.81%
Nisbah Pembayaran 268.80%
Jangkaan Pembayaran Dividen Seterusnya Feb 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 Tunai
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 Tunai
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 Tunai
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 Tunai
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 Tunai
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 Tunai
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 Tunai
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 Tunai
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 Tunai
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 Tunai
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 Tunai
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 Tunai
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 Tunai
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 Tunai
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 Tunai
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 Tunai
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 Tunai
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 Tunai
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 Tunai
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 Tunai
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 Tunai
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 Tunai
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 Tunai
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 Tunai
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 Tunai
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 Tunai
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 Tunai
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 Tunai
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 Tunai
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 Tunai
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 Tunai
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 Tunai
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 Tunai
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 Tunai
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 Tunai
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 Tunai
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 Tunai
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 Tunai
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 Tunai
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 Tunai
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 Tunai
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 Tunai
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 Tunai
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 Tunai
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 Tunai
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 Tunai
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 Tunai
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 Tunai
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 Tunai
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 3.28 2 1.44
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda